General Motors is drifting lower against a backdrop of compressing multiples, a stock down 5% on the month, and an October 20 earnings date that is now less than four weeks away.
The valuation story is the clearest change since the last note. The P/E multiple has slipped to 5.7x — down roughly 0.35 points over the past 30 days — while EV/EBITDA has eased to 7.6x. At just over one times book, GM is not priced for growth. Earnings revisions tell a more constructive story: the forward EPS growth factor ranks in the 92nd percentile of the ORTEX universe, and 30-day EPS momentum sits in the 74th percentile. The market is paying a bargain multiple for a company the Street thinks will grow earnings meaningfully — which is precisely why 13 of the covering analysts are at Buy or better, with a consensus target near $104, roughly 25% above Tuesday's close of $83.45.
Options positioning has grown slightly more defensive over the past month, though the move is measured rather than alarming. The put/call ratio is running at 0.73, about 1.2 standard deviations above its 20-day average of 0.69. That is not an extreme reading — the 52-week high is 1.10 — but the direction of travel is notable: the PCR was closer to 0.65 in late August and has drifted higher through September. Buyers of downside protection are quietly building ahead of the Q3 print. On the lending side, there is nothing to excite bears: short interest is only 2.4% of the free float, borrow costs are near-negligible at under 0.30%, and availability is essentially uncapped, with no meaningful pressure on the short side.
The peer landscape is worth noting this week. Ford fell 3% on the week — largely in line with GM's 2.2% decline — but European auto names took a harder hit. BMW dropped 5.2% and Porsche fell 6.7%. GM's relative resilience against that European washout is consistent with the momentum advantage flagged in recent ORTEX scoring. The short score is running at 33.7 — low and stable, reflecting no meaningful short-side build — and the days-to-cover sits at a comfortable 3.9 days per the latest FINRA fortnightly data.
The insider activity from late July is worth keeping in context. CEO Mary Barra sold approximately $14 million worth of stock on July 28 under a pre-arranged 10b5-1 plan, alongside option exercises. Executive Vice President Grant Dixton followed with a $3.5 million planned sale in early August. Both transactions were structured and scheduled — not discretionary — which limits their informational value. No open-market insider buying has appeared in the 90-day window, and the net insider position is negative by roughly $106 million in value terms. That is a bookkeeping reality of compensation mechanics rather than a conviction signal, but it is the full picture.
The last earnings print on July 21 produced an 8.4% single-day gain and a 19% five-day move — a significant beat that drove the wave of target raises that followed. The October 20 print therefore arrives with elevated expectations baked into the Street consensus, and the question heading into that date is whether the EV ramp and margin narrative has continued to hold through Q3.
See the live data behind this article on ORTEX.
Open GM on ORTEX →ORTEX Market Intelligence content is generated by AI from a snapshot of ORTEX's proprietary data. Content is informational only and does not constitute investment advice.
